Vancouver, BC / ACCESSWIRE / September 8th, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATTBF) (CSE:ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, today announced that Phytalytics LLC. ("Phytalab.com"), its 51% controlled US subsidiary, has received provisional certification from the Washington State Liquor Control Board. This milestone enables the lab to legally offer service to the new legal Cannabis industry.
Phytalab is proud to offer cannabis analysis laboratory services under provisional certification by the Washington State Liquor Control Board (WSLCB). Phytalab provides quality control testing services for I-502 Market Marijuana Producers and Processors. Chief Science Officer Dr. Michelle Sexton provided contracted services to the WSLCB for design of the certification quality control checklist for good laboratory practice.
Phytalab leads the industry in scientific expertise and education leading a team with 25 years combined experience in the quality control, product development and use of botanical medicines. Dr. Sexton and Dr. Kaleb Lund are published researchers and both come with extensive background and experience in analytical chemistry and phytochemical analysis.
Phytalab, originally founded as Phytalytics LLC, was the first laboratory to provide testing services in Washington State for medical Cannabis under State law. Dr. Sexton has dedicated her post-doctoral career to providing education on Cannabis use and guidance on quality control of Cannabis as botanical medicine. She contributed to the development of the analytical and quality control guidelines that Washington State adopted: the American Herbal Pharmacopoeia Cannabis Monograph.
"We measure components of the plant that contribute to it's overall character, such as the terpenoids. Legal Cannabis is a lot like the microbrew or wine industries, in that growers in WA dedicate themselves to breeding diverse genetics" says Dr. Sexton. "While THC may give Cannabis its' "kick", CBD is mellower and the terpenoids will guide the general "mood" of the variety. Knowing about these characteristics makes legal Cannabis more fun and interesting, as well as safe."
Rene David, CFO and COO of Abattis says: "Phytalab's Certification is a milestone that signifies a true connection to Abattis' mandate to be a science leader. I am extremely proud of Michelle and her team. The approval by the WSLCB offers proof to one of the many goals that Abattis works toward. We commit to our investors that we constantly work on achieving our licensing and implementation goals. We expect to see more success in Washington in the months and years to come".
Abattis CEO Mike Withrow commented, "This is one more milestone the team has achieved in building our overall plan. In addition to revenue, having a licensed lab will serve as a core competency in the Abattis group of companies that collects and stores a bank of tissue culture and logs invaluable data that can be repurposed within the Abattis group of companies and with strategic partners licensed to work with Cannabis."
Phytalab (www.phytalab.com) is PhytaLAB is the original Washington Cannabis testing facility setting the standard for Good Laboratory Practice in the Cannabis industry. We come to this industry with extensive herbal product experience. We offer a range of services for growers, producer/processors and retail facilities and provide data on which to base informed business decisions. Our background in Botanical Medicine puts us first when you are looking for help in product development for specific plant chemotypes and standardization for reproducibility and efficacy. PhytaLAB offers consulting services to both business and regulatory entities. We can help with questions around methods, safety, packaging and labeling, and more. Please contact us for our unrivaled expertise.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at email@example.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
SOURCE: Abattis Bioceuticals Corp.